{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:42:33Z","timestamp":1790714553148,"version":"4.1.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001352","name":"National University of Singapore","doi-asserted-by":"crossref","award":["R-148-000-185-133"],"award-info":[{"award-number":["R-148-000-185-133"]}],"id":[{"id":"10.13039\/501100001352","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.bcp.2015.07.036","type":"journal-article","created":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T06:39:47Z","timestamp":1438411187000},"page":"320-330","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Meclizine, a pregnane X receptor agonist, is a direct inhibitor and mechanism-based inactivator of human cytochrome P450 3A"],"prefix":"10.1016","volume":"97","author":[{"given":"Winnie Yin Bing","family":"Foo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hwee Ying","family":"Tay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric Chun Yong","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aik Jiang","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2015.07.036_bib0005","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1177\/0091270011414575","article-title":"Meclizine metabolism and pharmacokinetics: formulation on its absorption","volume":"52","author":"Wang","year":"2012","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.bcp.2015.07.036_bib0010","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1093\/hmg\/ddq464","article-title":"Meclizine is neuroprotective in models of Huntington\u2019s disease","volume":"20","author":"Gohil","year":"2011","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.bcp.2015.07.036_bib0015","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nbt.1606","article-title":"Nutrient-sensitized screening for drugs that shift energy metabolism from mitochondrial respiration to glycolysis","volume":"28","author":"Gohil","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.bcp.2015.07.036_bib0020","doi-asserted-by":"crossref","first-page":"35387","DOI":"10.1074\/jbc.M113.489237","article-title":"Meclizine inhibits mitochondrial respiration through direct targeting of cytosolic phosphoethanolamine metabolism","volume":"288","author":"Gohil","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2015.07.036_bib0025","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1210\/en.2014-1914","article-title":"Meclozine promotes longitudinal skeletal growth in transgenic mice with achondroplasia carrying a gain-of-function mutation in the FGFR3 gene","volume":"156","author":"Matsushita","year":"2015","journal-title":"Endocrinology"},{"key":"10.1016\/j.bcp.2015.07.036_bib0030","first-page":"105","article-title":"Biotransformation of meclozine in the human body","volume":"26","author":"Goenechea","year":"1988","journal-title":"J. Clin. Chem. Clin. Biochem."},{"key":"10.1016\/j.bcp.2015.07.036_bib0035","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0022-3565(25)22379-5","article-title":"Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians","volume":"270","author":"Shimada","year":"1994","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcp.2015.07.036_bib0040","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1124\/dmd.30.12.1311","article-title":"Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions","volume":"30","author":"Yuan","year":"2002","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2015.07.036_bib0045","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1172\/JCI3703","article-title":"The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions","volume":"102","author":"Lehmann","year":"1998","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bcp.2015.07.036_bib0050","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","article-title":"Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation","volume":"138","author":"Zanger","year":"2013","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2015.07.036_bib0055","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2165\/00003088-199835050-00003","article-title":"Inhibition and induction of cytochrome P450 and the clinical implications","volume":"35","author":"Lin","year":"1998","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.bcp.2015.07.036_bib0060","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1124\/jpet.110.175927","article-title":"Differential effect of meclizine on the activity of human pregnane X receptor and constitutive androstane receptor","volume":"336","author":"Lau","year":"2011","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcp.2015.07.036_bib0065","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2174\/156802611794480891","article-title":"Strategies and chemical design approaches to reduce the potential for formation of reactive metabolic species","volume":"11","author":"Argikar","year":"2011","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.bcp.2015.07.036_bib0070","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/j.2042-7158.2010.01202.x","article-title":"Mechanism of cytochrome P450-3A inhibition by ketoconazole","volume":"63","author":"Greenblatt","year":"2011","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.bcp.2015.07.036_bib0075","first-page":"1","article-title":"Effect of common organic solvents on in vitro cytochrome P450-mediated metabolic activities in human liver microsomes","volume":"26","author":"Chauret","year":"1998","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2015.07.036_bib0080","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1124\/dmd.108.022178","article-title":"Prediction of the effect of erythromycin, diltiazem, and their metabolites, alone and in combination, on CYP3A4 inhibition","volume":"37","author":"Zhang","year":"2009","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2015.07.036_bib0085","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1021\/tx7002504","article-title":"Mechanism-based inactivation of human cytochromes p450s: experimental characterization, reactive intermediates, and clinical implications","volume":"21","author":"Hollenberg","year":"2008","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.bcp.2015.07.036_bib0090","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1124\/mol.110.065839","article-title":"Mechanism-based inactivation of cytochrome P450 3A4 by lapatinib","volume":"78","author":"Teng","year":"2010","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bcp.2015.07.036_bib0095","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1124\/dmd.112.044958","article-title":"Interaction of lapatinib with cytochrome P450 3A5","volume":"40","author":"Chan","year":"2012","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2015.07.036_bib0100","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1056-8719(02)00168-5","article-title":"A novel testosterone 6 beta-hydroxylase activity assay for the study of CYP3A-mediated metabolism, inhibition, and induction in vitro","volume":"46","author":"Fayer","year":"2001","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.bcp.2015.07.036_bib0105","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1124\/dmd.32.6.647","article-title":"Validated assays for human cytochrome P450 activities","volume":"32","author":"Walsky","year":"2004","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2015.07.036_bib0110","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1006\/abbi.1998.0679","article-title":"Mechanism-based inactivation of cytochromes P450 2E1 and 2B1 by 5-phenyl-1-pentyne","volume":"354","author":"Roberts","year":"1998","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.bcp.2015.07.036_bib0115","doi-asserted-by":"crossref","first-page":"5929","DOI":"10.1021\/bi992765t","article-title":"Elucidation of distinct ligand binding sites for cytochrome P450 3A4","volume":"39","author":"Hosea","year":"2000","journal-title":"Biochemistry"},{"key":"10.1016\/j.bcp.2015.07.036_bib0120","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1021\/tx034143l","article-title":"Mechanism-based inactivation of cytochrome P450 3A4 by 4-ipomeanol","volume":"17","author":"Alvarez-Diez","year":"2004","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.bcp.2015.07.036_bib0125","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1021\/tx050092b","article-title":"Zafirlukast metabolism by cytochrome P450 3A4 produces an electrophilic alpha,beta-unsaturated iminium species that results in the selective mechanism-based inactivation of the enzyme","volume":"18","author":"Kassahun","year":"2005","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.bcp.2015.07.036_bib0130","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1124\/jpet.301.1.160","article-title":"Mechanism-based inactivation of cytochrome P450 3A4 by 17\u03b1-ethynylestradiol: evidence for heme destruction and covalent binding to protein","volume":"301","author":"Lin","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcp.2015.07.036_bib0135","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/S0022-3565(25)12214-3","article-title":"Potent and selective inactivation of human liver microsomal cytochrome P-450 isoforms by L-754,394, an investigational human immune deficiency virus protease inhibitor","volume":"275","author":"Chiba","year":"1995","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcp.2015.07.036_bib0140","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0022-3565(25)29498-8","article-title":"Chronic administration of chlorcyclizine and meclizine to rats: accumulation of a metabolite formed by piperazine ring cleavage","volume":"185","author":"Gaertner","year":"1973","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcp.2015.07.036_bib0145","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.2174\/092986708785747625","article-title":"Physicochemical, pharmacological and pharmacokinetic properties of the zwitterionic antihistamines cetirizine and levocetirizine","volume":"15","author":"Chen","year":"2008","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.bcp.2015.07.036_bib0150","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1021\/tx0200109","article-title":"Cytochrome P450 3A4-mediated bioactivation of raloxifene: irreversible enzyme inhibition and thiol adduct formation","volume":"15","author":"Chen","year":"2002","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.bcp.2015.07.036_bib0155","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0090-9556(24)15118-5","article-title":"Drug interactions with calcium channel blockers: possible involvement of metabolite\u2013intermediate complexation with CYP3A","volume":"28","author":"Ma","year":"2000","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2015.07.036_bib0160","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1124\/dmd.109.026526","article-title":"Evaluation of multiple in vitro systems for assessment of CYP3A4 induction in drug discovery: human hepatocytes, pregnane X receptor reporter gene, and Fa2N-4 and HepaRG cells","volume":"37","author":"McGinnity","year":"2009","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2015.07.036_bib0165","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2174\/1389200054021799","article-title":"A comprehensive listing of bioactivation pathways of organic functional groups","volume":"6","author":"Kalgutkar","year":"2005","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.bcp.2015.07.036_bib0170","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1124\/dmd.114.060459","article-title":"Mechanism-based inactivation of human cytochrome P450 3A4 by two piperazine-containing compounds","volume":"42","author":"Bolles","year":"2014","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2015.07.036_bib0175","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1111\/j.1476-5381.2011.01732.x","article-title":"Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates","volume":"165","author":"Filppula","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bcp.2015.07.036_bib0180","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0022-3565(24)37800-0","article-title":"Microsomal metabolism of delavirdine: evidence for mechanism-based inactivation of human cytochrome P450 3A","volume":"287","author":"Voorman","year":"1998","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcp.2015.07.036_bib0185","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1124\/jpet.104.075416","article-title":"Mechanism-based inactivation of CYP3A by HIV protease inhibitors","volume":"312","author":"Ernest","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcp.2015.07.036_bib0190","first-page":"552","article-title":"Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4\/3A5: mechanism-based inactivation of cytochrome P4503A by ritonavir","volume":"26","author":"Koudriakova","year":"1998","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2015.07.036_bib0195","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1124\/dmd.108.021493","article-title":"Differential inhibition of cytochromes P450 3A4 and 3A5 by the newly synthesized coumarin derivatives 7-coumarin propargyl ether and 7-(4-trifluoromethyl) coumarin propargyl ether","volume":"36","author":"Sridar","year":"2008","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2015.07.036_bib0200","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1124\/dmd.32.10.1083","article-title":"Differences in the inhibition of cytochromes P450 3A4 and 3A5 by metabolite\u2013inhibitor complex-forming drugs","volume":"32","author":"McConn","year":"2004","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2015.07.036_bib0205","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1124\/dmd.104.001834","article-title":"Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil","volume":"33","author":"Wang","year":"2005","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2015.07.036_bib0210","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1124\/dmd.112.046144","article-title":"Discovery of a highly selective CYP3A4 inhibitor suitable for reaction phenotyping studies and differentiation of CYP3A4 and CYP3A5","volume":"40","author":"Li","year":"2012","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2015.07.036_bib0215","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1124\/dmd.104.003475","article-title":"Automated screening with confirmation of mechanism-based inactivation of CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP1A2 in pooled human liver microsomes","volume":"33","author":"Lim","year":"2005","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2015.07.036_bib0220","doi-asserted-by":"crossref","first-page":"e1000594","DOI":"10.1371\/journal.pcbi.1000594","article-title":"Challenges predicting ligand\u2013receptor interactions of promiscuous proteins: the nuclear receptor PXR","volume":"5","author":"Ekins","year":"2009","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.bcp.2015.07.036_bib0225","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1124\/dmd.30.7.795","article-title":"CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes","volume":"30","author":"Luo","year":"2002","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2015.07.036_bib0230","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1111\/j.1365-2036.2005.02683.x","article-title":"Intestinal fluid volumes and transit of dosage forms as assessed by magnetic resonance imaging","volume":"22","author":"Schiller","year":"2005","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2015.07.036_bib0235","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/S0022-3565(25)26997-X","article-title":"Metabolism of meclizine in the rat","volume":"147","author":"Narrod","year":"1965","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcp.2015.07.036_bib0240","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1211\/jpp.61.05.0002","article-title":"Cytochrome P450-mediated metabolism in the human gut wall","volume":"61","author":"Thelen","year":"2009","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.bcp.2015.07.036_bib0245","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1517\/17425255.3.1.67","article-title":"Clinical relevance of the small intestine as an organ of drug elimination: drug\u2013fruit juice interactions","volume":"3","author":"Paine","year":"2007","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.bcp.2015.07.036_bib0250","doi-asserted-by":"crossref","first-page":"762","DOI":"10.2174\/138920010794328922","article-title":"Predicting drug\u2013drug interactions involving the inhibition of intestinal CYP3A4 and P-glycoprotein","volume":"11","author":"Tachibana","year":"2010","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.bcp.2015.07.036_bib0255","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.pharmthera.2012.08.001","article-title":"Mechanisms underlying food\u2013drug interactions: inhibition of intestinal metabolism and transport","volume":"136","author":"Won","year":"2012","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2015.07.036_bib0260","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1124\/dmd.114.059147","article-title":"Assessment of intestinal availability (FG) of substrate drugs of cytochrome P450s by analyzing changes in pharmacokinetic properties caused by drug\u2013drug interactions","volume":"42","author":"Hisaka","year":"2014","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2015.07.036_bib0265","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/sj.clpt.6100452","article-title":"Effect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected patients","volume":"84","author":"Wyen","year":"2008","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2015.07.036_bib0270","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/0140-6736(91)90872-M","article-title":"Interaction of citrus juices with felodipine and nifedipine","volume":"337","author":"Bailey","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2015.07.036_bib0275","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1124\/dmd.108.024968","article-title":"Identification of a cranberry juice product that inhibits enteric CYP3A-mediated first-pass metabolism in humans","volume":"37","author":"Ngo","year":"2009","journal-title":"Drug Metab. Dispos."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295215004256?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295215004256?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T21:00:38Z","timestamp":1748552438000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295215004256"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":55,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["S0006295215004256"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2015.07.036","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Meclizine, a pregnane X receptor agonist, is a direct inhibitor and mechanism-based inactivator of human cytochrome P450 3A","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2015.07.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}